Medipixel, Inc.

Medipixel is a medical software company specializing in artificial intelligence-driven diagnostic solutions for interventional cardiology and cerebrovascular procedures. The company develops Software as a Medical Device (SaMD) products that integrate seamlessly into cath lab workflows to provide real-time quantitative analysis of cardiovascular and cerebrovascular conditions. MPXA (Medipixel X-ray Angiography) is their flagship product—an FDA 510(k)-cleared, MFDS-certified AI platform that automatically analyzes angiographic images in approximately 1.8 seconds, supporting clinician decision-making without workflow interruption. MPXA incorporates deep learning technology for vessel segmentation, lesion analysis, and quantitative assessment, with demonstrated equivalence to OCT (optical coherence tomography) in cardiovascular procedures. MPNeuro, their cerebrovascular platform, provides 3D digital twin modeling and analysis for interventional neuroradiology, achieving Mean Absolute Percentage Error of less than 1% in quantitative assessment. Medipixel was founded in South Korea and established a U.S. subsidiary in 2023. The company has secured significant funding (Series B $12.8M in 2023) and is preparing for IPO (2024). Their solutions serve interventional cardiologists and neurointerventionalists in the United States, Korea, Southeast Asia, and Middle East markets. The company holds multiple international certifications and has won industry recognition including TIME's World's Top 400 HealthTech Companies, MedTech Innovator award, and ACC Innovation Pitch Challenge.